Srivathsan Ranganathan

Dr. Srivathsan Ranganathan

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2017 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
SVS. Vangaveti
S. Vangaveti
RDR. J. D'ESposito
R. J. D'ESposito
JLJ. L. Lippens
J. L. Lippens
DFD. Fabris
D. Fabris
SRSrivathsan Ranganathan
Srivathsan Ranganathan
We developed a five bead model that facilitates calculation of collision cross sections of coarse grained structures of nucleic acids, enabling their structural elucidation using Ion Mobility Spectrometry–Mass Spectrometry (IMS-MS).

24 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
EOE. Sila Ozdemir
E. Sila Ozdemir
HLHillary H. Le
Hillary H. Le
AYAdem Yildirim
Adem Yildirim
SRSrivathsan Ranganathan
Srivathsan Ranganathan
The COVID-19 pandemic began in 2019, but it is still active. The development of an effective vaccine reduced the number of deaths; however, a treatment is still needed. Here, we aimed to inhibit viral entry to the host cell by inhibiting spike (S) protein cleavage by several proteases. We developed a computational pipeline to repurpose FDA-approved drugs to inhibit protease activity and thus prevent S protein cleavage. We tested some of our drug candidates and demonstrated a decrease in protease activity. We believe our pipeline will be beneficial in identifying a drug regimen for COVID-19 patients.

7 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
EOE. Sila Ozdemir
E. Sila Ozdemir
HLHillary H. Le
Hillary H. Le
AYAdem Yildirim
Adem Yildirim
SRSrivathsan Ranganathan
Srivathsan Ranganathan
The COVID-19 pandemic began in 2019, but it is still active. The development of an effective vaccine reduced the number of deaths; however, a treatment is still needed. Here, we aimed to inhibit viral entry to the host cell by inhibiting Spike (S) protein cleavage by several proteases. We develop a computational pipeline to repurpose FDA-approved drugs to inhibit protease activity and thus prevent S protein cleavage. We tested some of our drug candidates and demonstrated a decrease in protease activity. We believe our pipeline will be beneficial in identifying a drug regimen for COVID-19 patients.

25 August 2017 in Biomolecules
Verified
Journal Article
Open access
PDF file
KOKhadijah Onanuga
Khadijah Onanuga
TBThomas J. Begley
Thomas J. Begley
ACAlan Austin Chen
Alan Austin Chen
SRSrivathsan Ranganathan
Srivathsan Ranganathan
There are over 100 enzyme-catalyzed modifications on transfer RNA (tRNA) molecules. The levels and identity of wobble uridine (U) modifications are affected by environmental conditions and diseased states, making wobble U detection a potential biomarker for exposures and pathological conditions. The current detection of RNA modifications requires working with nucleosides in bulk samples. Nanopore detection technology uses a single-molecule approach that has the potential to detect tRNA modifications. To evaluate the feasibility of this approach, we have performed all-atom molecular dynamics (MD) simulation studies of a five-layered graphene nanopore by localizing canonical and modified uridine nucleosides. We found that in a 1 M KCl solution with applied positive and negative biases not exceeding 2 V, nanopores can distinguish U from 5-carbonylmethyluridine (cm5U), 5-methoxycarbonylmethyluridine (mcm5U), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U), and 5-methoxycarbonylmethyl-2′-O-methyluridine (mcm5Um) based on changes in the resistance of the nanopore. Specifically, we observed that in nanopores with dimensions less than 3 nm diameter, a localized mcm5Um and mcm5U modifications could be clearly distinguished from the canonical uridine, while the other modifications showed a modest yet detectable decrease in their respective nanopore conductance. We have compared the results between nanopores of various sizes to aid in the design, optimization, and fabrication of graphene nanopores devices for tRNA modification detection.

27 November 2024 in Biophysica
Verified
Journal Article
Open access
PDF file
EOE. Sila Ozdemir
E. Sila Ozdemir
JTJessica Tolley
Jessica Tolley
FGFlorian Goncalves
Florian Goncalves
MGMichelle Gomes
Michelle Gomes
EWEli Wagnell
Eli Wagnell
SRSrivathsan Ranganathan
Srivathsan Ranganathan
The variable heavy chain fragments derived from camelid antibodies, called VHHs or nanobodies, have recently shown promise as high-affinity reagents. They offer higher stability compared to conventional antibodies and fragments thereof. Furthermore, their smaller size (~15–20 kDa) allows better targeting of molecules localized inside the cell and in crowded environments, like tissues and protein aggregates. Despite these advantages, nanobody clones screened using phage display can suffer from poor soluble expression, which we hypothesized is due to the presence of hydrophobic hotspots on their surface. In this work, we propose a novel, computationally guided workflow for screening and production of nanobody binders for optimized expression. After an initial round of phage display screens against our target (K-Ras), we modeled the lead candidates to generate spatial aggregation propensity (SAP) maps to highlight the hydrophobic hotspots with single amino acid resolution, which were subsequently used to guide mutagenesis of the binders for soluble expression. We followed two approaches to perform point hydrophilic mutations: (i) performing point hydrophilic mutations in the hydrophobic hotspots; (ii) combining point mutation resulting from a round of random mutagenesis that show favorable SAP scores. Both approaches led to a remarkable increase in soluble expression, which allowed production and characterization of their binding to their target (K-Ras) on soluble ELISA and biolayer interferometry. We observed that the latter approach resulted in clones with stronger binding affinity compared to the former approach. Our results emphasize the need to perform a round of random mutagenesis to identify point mutations, which can then be used in an in silico guided pipeline to identify the right combination of mutations for high soluble expression.

26 March 2025 in Small
Verified
Journal Article
Open access
ESElla Stimson
Ella Stimson
DSDelaney Shea
Delaney Shea
MGMichelle Gomes
Michelle Gomes
SRSrivathsan Ranganathan
Srivathsan Ranganathan
SMSarah Mitchell
Sarah Mitchell
SIStuart D. Ibsen
Stuart D. Ibsen
Protease activity is an emerging biomarker for cancer detection as activity levels are often increased in tumor tissue compared to healthy tissue. Of particular interest is the activity of proteases carried by extracellular vesicle (EV) nanoparticles which are oversecreted by tumors into circulation. Current methods to analyze the activity of proteases bound to EVs require complex multi‐instrument sample processing to separate EVs from plasma to quantify protease activity. This makes EV‐based protease activity detection a challenge for diagnostic or point‐of‐care applications. Here, a method is reported that manipulates EV nanoparticles and charged molecular byproducts from protease activity using two different electrokinetic phenomena generated by a single electrode microarray within a microfluidic channel. Dielectrophoresis is first generated to recover EVs carrying active trypsin‐like proteases from human plasma followed by electrophoresis for subsequent analysis of peptide cleavage products indicating protease activity. This method demonstrates signal amplification through protease catalytic activity in combination with concentrating mechanisms of dielectrophoresis and electrophoresis. Using this approach, a significant difference in protease activity is observed between patients with pancreatic cancer and benign cysts. This demonstrates dual‐electrokinetic chip‐based technology as a useful tool to manipulate different sized and charged analytes in a single device enabling future clinical translation of EV‐based protease diagnostics.